

**Table 8. Comparison of Anatomic Outcomes in Patients Treated with Laser + Ranibizumab versus Ranibizumab Alone with Last Observation Carried Forward**

	BRVO			CRVO		
	RBZ + Laser (n=20)	RBZ alone (n=19)	p-value	RBZ + Laser (n=18)	RBZ alone (n=20)	p-value
<b>Week 48 Completers</b>						
<b>Mean CST</b>						
<b>Week 24, <math>\mu\text{m}</math></b>	311.4+18.7	347.7+31.6	0.82	323.0+19.6	309.8+32.5	0.16
<b>Week 48</b>	381.5+34.8	320.3+23.0	0.15	417.7+33.5	327.4+33.7	0.01
<b>Change from baseline to week 48</b>	70.0+27.9	-27.0+38.7	0.05	94.7+27.4	4.7+38.3	0.03
<b>Percentage of patients with CST<math>\leq</math>320 <math>\mu\text{m}</math> at 48 weeks, (n)</b>	45.0 (9.0)	63.2 (12.0)	0.13	38.9 (7.0)	70.0 (14.0)	0.11
<b>Week 96 Completers</b>						
<b>Mean CST</b>						
<b>Week 24, <math>\mu\text{m}</math></b>	311.4+18.7	347.7+31.6	0.82	323.0+19.6	309.8+32.5	0.16
<b>Week 96</b>	332.5+26.9	308.3+29.2	0.27	342.8+22.6	338.1+51.2	0.25
<b>Change from baseline to week 96</b>	21.1+26.3	-39.4+41.4	0.23	19.8+16.0	28.3+43.8	0.47
<b>Percentage of patients with CST<math>\leq</math>320 <math>\mu\text{m}</math> at 96 weeks, (n)</b>	55.0 (11.0)	78.9 (15.0)	0.33	50.0 (9.0)	75.0 (15.0)	0.21
<b>Week 144 Completers</b>						
<b>Mean CST</b>						
<b>Week 24, <math>\mu\text{m}</math></b>	311.4+18.7	347.7+31.6	0.82	323.0+19.6	309.8+32.5	0.16
<b>Week 144</b>	342.5+27.7	338.0+36.0	0.33	377.0+32.1	368.6+54.0	0.36
<b>Change from baseline to week 144</b>	31.2+24.9	-9.7+46.1	0.44	50.8+32.7	58.8+53.3	0.85
<b>Percentage of patients with CST<math>\leq</math>320 <math>\mu\text{m}</math> at 144 weeks, (n)</b>	60.0 (12.0)	73.7 (14.0)	0.67	44.4 (8.0)	65.0 (13.0)	0.34